OABI · OmniAb, Inc.

Current Thesis

OmniAb’s milestone re-rating depends on repeat partner payments lifting full-year revenue guidance above $36 million at the next results; a weekly close below $3.82 ends the price thesis. The company’s 2026-08-06 results established the earnings evidence, and its 2026-08-17 Lilly agreement extended the licensing story. Those disclosures support a repeat-payment hypothesis, but the sample is too small to establish recurring milestone revenue.

The narrative is maturing — the adjusted close declined from $4.47 on 2026-08-28 to $4.07 on 2026-09-11, while the 14-day relative strength index (RSI) cooled from 77.3 to 45.5. This is an inference from price momentum, not a measurement of investor flows. The October 6 Investor and Analyst Day, already disclosed with the August results, adds a substantive presentation date omitted from the previous calendar. OmniAb quarterly results

Bullish and bearish views on OmniAb, Inc.

The model's bull view on OmniAb, Inc. (OABI), in brief: Milestone revenue supplied the improvement. The bear view: Guidance does not establish repetition. First-half 2026 revenue was $27.8 million against management’s 2026-08-06 full-year outlook of $32–36 million. The inference is that management had not endorsed sustained second-quarter revenue at that disclosure date. Headline economics… Both cases follow in full.

Bull Case

• Milestone revenue supplied the improvement. OmniAb’s 2026-08-06 results reported second-quarter revenue of $13.415 million, including $9.515 million of license and milestone revenue. Management raised full-year 2026 revenue guidance to $32–36 million from $28–33 million; these are reported results and guidance, not evidence that the quarterly payment pace repeats.
• Lilly expanded the licensing opportunity. The 2026-08-17 agreement provides an undisclosed upfront payment, up to $370 million in research, development and commercial milestones, and tiered royalties. The contingent payments support the opportunity set; they do not establish a collection schedule. OmniAb agreement announcement
• Partner breadth supports the hypothesis. The 2026-08-06 investor presentation reported 110 active partners and 425 active programs, including 34 clinical-stage or approved programs. More than 98% carried contracted future economics; these counts describe contractual exposure, without measuring the probability or timing of payment.

Bear Case

• Guidance does not establish repetition. First-half 2026 revenue was $27.8 million against management’s 2026-08-06 full-year outlook of $32–36 million. The inference is that management had not endorsed sustained second-quarter revenue at that disclosure date.
• Headline economics remain contingent. The 2026-08-17 Lilly release did not quantify the upfront payment or assign dates to the potential $370 million of milestones. The agreement therefore cannot substantiate a specific near-term revenue forecast. OmniAb agreement announcement
• Equity capacity remains a caveat. The second-quarter 2026 Form 10-Q, reported on 2026-08-06, disclosed approximately $88.3 million of unused at-the-market equity issuance capacity and no sales through that program during the first half of 2026. This establishes issuance capacity at that date, not subsequent issuance.

Setup & Price Structure

The adjusted daily series records a $4.07 close on 2026-09-11, 19.2% below its $5.04 52-week high, despite a three-month price increase of 79.3%. The $3.82 close on the 2026-08-17 Lilly announcement remains the research invalidation reference. The $3.38–$3.43 closing shelf recorded during 2026-08-10 through 2026-08-14 is the earlier market structure beneath it.

The current RSI of 45.5, measured on 2026-09-11, does not preserve the momentum reading of 77.3 recorded on 2026-08-28. No moving-average level, volume comparison or short-interest series accompanies these observations, so neither extension above a rising average nor crowded ownership can be established.

Retail-facing coverage clustered around the 2026-08-17 announcement: Benzinga published a Lilly-deal explainer, a market-moving-news item and gainer coverage that day. That is observable headline clustering. The sample is too small to support a claim about retail participation or positioning.

Catalyst Calendar (next 30 days)

• 2026-10-06 — Investor and Analyst Day. Announced with the 2026-08-06 results, the agenda includes management presentations, panels and a laboratory tour. The relevant unresolved question is whether management supplies payment timing or revenue visibility beyond the August disclosures. Company quarterly-results announcement
• ~2026-11-05, est. Third-quarter results. This date remains unconfirmed and falls outside the next 30 days. The results are the later fundamental test: whether repeat licensing and milestone activity lifts the full-year outlook above the $36 million upper end announced on 2026-08-06.

Elapsed catalysts

• 2026-09-15 — H.C. Wainwright conference. OmniAb’s 2026-08-26 announcement schedules a corporate overview and investor meetings. The event provides a venue for updated disclosure; the announcement promises no new agreement or financial guidance. Company conference announcement (passed 5d ago)

What Would Change Our Mind

Loss of the Lilly-announcement reference would break the price structure: a weekly close below $3.82, the adjusted close recorded on 2026-08-17, invalidates this re-rating thesis. The earlier August shelf does not extend that condition.

For grading, the affirmative case requires both full-year 2026 revenue guidance above $36 million at the next results and a weekly close above the $5.04 high reported in the 2026-09-11 price record before invalidation. These are analytical confirmation conditions, not company forecasts. Guidance remaining within the August range at the next results would fail the fundamental test even if the price condition survives.

The 2026-09-09 conference date has elapsed. If the September 15 conference and October 6 Investor and Analyst Day also pass without a new partner agreement, quantified payment timing or revised guidance, the presentation calendar will not have supplied additional evidence for repeat payments.

Correlation Notes

This remains a single-company licensing thesis: the 2026-08-06 partner-program disclosure and 2026-08-17 Lilly agreement supply its evidence. No matched sector-return series or measured correlation accompanies the 2026-09-11 price record, so a biotechnology group move cannot be credited with confirming the case. Lilly’s role is contractual; the agreement alone does not establish that OmniAb shares track Lilly shares.